SC
EVMN icon

Stempoint Capital’s Evommune Inc EVMN Stock Holding History

Stempoint Capital’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-193,777
Closed -$4.39M – 116
2026
Q1 		$4.39M Buy
193,777
+125,581
+184% +$2.84M 0.84% 37
2025
Q4 		$1.17M Buy
+68,196
New +$1.28M 0.2% 65

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Stempoint Capital's EVMN Position: Q2 2026 in Review

Stempoint Capital sold out of Evommune Inc (EVMN) in Q2 2026, closing a stake of 193,777 shares — an estimated $4.39M sold.

Stempoint Capital first reported a position in EVMN in Q4 2025 and held it in 2 quarters. The position peaked at $4.39M in Q1 2026. 105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • Stempoint Capital reported no remaining Evommune Inc position as of Q2 2026 after selling out during the quarter.
  • Stempoint Capital sold 193,777 Evommune Inc shares in Q2 2026, an estimated $4.39M.
  • Stempoint Capital first reported a position in Evommune Inc in Q4 2025 and held it in 2 quarters.
  • Stempoint Capital's Evommune Inc position peaked at $4.39M in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.